A1C variability and the risk of microvascular complications in type 1 diabetes: Data from the diabetes control and complications trial

Diabetes Care

Volumn 31, Issue 11, 2008, Pages 2198-2202

  Kilpatrick, Eric S ^a   Rigby, Alan S ^b   Atkin, Stephen L ^c  

^a HULL ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; RISK ASSESSMENT; SEX DIFFERENCE; BLOOD; DIABETIC NEUROPATHY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS;

DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS;

EID: 58849150951     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-0864     Document Type: Article

References (26)

1. Monnier L, Colette C: Glycemic variability: should we and can we prevent it? Diabetes Care 31:150-154, 2008
2. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
3. 1c) to the risk of development and progression of retinop- athy in the diabetes control and complications trial. Diabetes 44:968-983, 1995
4. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). lancet 352:837-853, 1998
5. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and micro- vascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
6. Brownlee M, Hirsch IB: Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 295:1707-1708, 2006
7. Service FJ, O'Brien PC: The relation of gly- caemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabe- tologia 44:1215-1220, 2001
8. Kilpatrick ES, Rigby AS, Atkin SL: The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486-1490, 2006
9. 1c in the prediction of cardiovascular diseasein type 1. Diabetologia 51:365-371, 2008
10. Lachin JM, Genuth S, Nathan DM, Zin- man B, Rutledge BN: The effect of glyce- mic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial-revisited. Diabetes 57:995-1001, 2008
11. 1c: implications for the assessment of glycemic control. Clin Chem 53:897-901, 2007
12. Prince C, Becker D, Costacou T, Miller R, Orchard T: Changes in glycaemic control and risk of coronary artery disease in type
13. diabetes mellitus: findings from the Pittsburgh Epidemiology of Diabetes Complications Study (EDC). Diabetologia 50:2280-2288, 2007
14. The Diabetes Control and Complications Trial Research Group: Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial. Diabetes Care 23:1084-1091, 2000
15. Schemper M, Henderson R: Predictive accuracy and explained variation in Cox regression. Biometrics 56:249-255, 2000
16. Quagliaro L, Piconi L, Assaloni R, Marti- nelli L, Motz E, Ceriello A: Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52:2795-2804, 2003
17. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol J-P, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295:1681-1687, 2006
18. Wentholt I, Kulik W, Michels R, Hoekstra J, DeVries J: Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia 51:183-190, 2008
19. 2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99: 224-229, 1999
20. The Diabetes Control and Complications Trial Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563-2569, 2002
21. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653, 2005
22. Ihnat M, Thorpe J, Ceriello A: Hypothesis: the 'metabolic memory,' the new challenge of diabetes. Diabet Med 24:582-586, 2007
23. The Kroc Collaborative Study Group: Blood glucose control and the evolution of diabetic-retinopathy and albuminuria: a preliminary multicenter trial. N Engl J Med 311:365-372, 1984
24. The Diabetes Control and Complications Trial Research Group: Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 116:874-886, 1998
25. Smith LEH, KopchickJJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, SchaefferJM: Essential role of growth hormone in ischemia-induced retinal neo- vascularization. Science 276:1706-1709, 1997
26. 1c levels than glucose instability: an analysis of data from the Diabetes Control and Complications Trial. Diabetes Care 29:352-355, 2006